Bookmark and Share
emivirine (CID 65013) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(57)
 
 
Inconclusive(7)
 
 
Unspecified(46)
 
 
BioAssay Types:
Literature(110)
 
 
 
 
BioActivity Types:
IC50(37)
 
 
 
EC50(28)
 
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 110    Data Row: 110   Total Pages: 3   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103209563]
EC50 0.001Compound was tested for its inhibition of HIV-1 induced focus formation in MAGI-CCR5 cells in strains like NL4-3 [AID102401, Type: Literature]
View
2
[SID103209563]
EC50 0.002Effective concentration required against wild type HIV-1 reverse transcriptase [AID199996, Type: Literature]
View
3
[SID103209563]
EC50 0.003The effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus A012D strain [AID105514, Type: Literature]
View
4
[SID103209563]
IC50 0.004Inhibitory activity of compound on p24 production in peripheral blood mononuclear cells infected with HIV strain HTLV IIIB wild type. [AID152661, Type: Literature]
View
5
[SID103209563]
IC50 0.004Ability to inhibit the replication of HTLV IIIb strain of HIV-1 p24 antigen production in PBMC [AID155272, Type: Literature]
View
6
[SID103209563]
EC50 0.004The effective concentration required to achieve 50% protection of human peripheral blood lymphocytes against the cytopathic effect of HIV-1 virus HTLV-IIIB strain [AID157405, Type: Literature]
View
7
[SID103209563]
EC50 0.004Inhibition of HIV-1 reverse transcriptase at 37 degree Centigrade [AID200003, Type: Literature]
View
8
[SID103209563]
IC50 0.004Compound was evaluated for inhibition of p24 production in HIV infected peripheral blood mononuclear cells [AID155289, Type: Literature]
View
9
[SID103209563]
IC50 0.004Anti-HIV activity by its ability to inhibit the replication of HIV-1 strain HTLV IIIB in peripheral blood mononuclear cells (PBMC) [AID155278, Type: Literature]
View
10
[SID103209563]
EC50 0.004Compound was tested for its inhibition of HIV-1 induced focus formation in MAGI-CCR5 cells in strains like IIIB [AID102399, Type: Literature]
View
11
[SID103209563]
EC50 0.0042Inhibitory concentration against HIV-1 reverse transcriptase [AID200009, Type: Literature]Reverse transcriptase/RNaseH [gi:82310930]
View
12
[SID103209563]
EC50 0.0042Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus. [AID105513, Type: Literature]
View
13
[SID103209563]
ED50 0.005Effective dose required for 50% inhibition of HIV-1 antigen production in MT-4 cultures [AID104311, Type: Literature]
View
14
[SID103209563]
ED50 0.005Effective dose of compound required to inhibit 50% of HIV-1 antigen production in MT-4 cultures. [AID105530, Type: Literature]
View
15
[SID103209563]
IC50 0.008Anti-HIV-1 activity against LAI strain in MT-4 cells by the MTT method [AID105701, Type: Literature]
View
16
[SID103209563]
IC50 0.008Concentration required to inhibit 50% viral production of human immunodeficiency virus type 1 (HIV-1-IIIB) [AID248354, Type: Literature]
View
17
[SID103209563]
IC50 0.008Inhibitory activity against wild type HIV-1 LAI cell line [AID247526, Type: Literature]
View
18
[SID103209563]
IC50 0.008Inhibitory activity against HIV-1 reverse transcriptase [AID198238, Type: Literature]
View
19
[SID103209563]
EC50 0.02Effective concentration required against L100I mutant HIV-1 reverse transcriptase [AID199991, Type: Literature]
View
20
[SID103209563]
EC50 0.03Effective concentration of compound to inhibit human immunodeficiency virus HIV-1 wild type strain IIIB multiplication in CEM wild type cells [AID246557, Type: Literature]
View
21
[SID103209563]
EC50 0.03Effective concentration of compound to inhibit human immunodeficiency virus HIV-1 wild type strain IIIB multiplication in MT-4 infected cells [AID246558, Type: Literature]
View
22
[SID103209563]
IC50 0.03Inhibitory activity against HIV-1 mutant strain 179E [AID247500, Type: Literature]
View
23
[SID103209563]
EC50 0.03Antiviral activity against HIV1 HTLV-3B [AID313191, Type: Literature]
View
24
[SID103209563]
EC50 0.03Concentration required to achieve 50% protection of MT-4 cells from HIV-1-induced cytopathogenicity. [AID105143, Type: Literature]
View
25
[SID103209563]
EC50 0.03Effective dose required to achieve protection of MT-4 cells from HIV-1 induced cytopathogenicity [AID105320, Type: Literature]
View
26
[SID103209563]
EC50 0.03Effective concentration against HIV-1 induced cytopathogenicity in MT-4 cells [AID106978, Type: Literature]
View
27
[SID103209563]
IC50 0.032Anti-HIV-1 activity against K103N strain in MT-4 cells by the MTT method [AID105695, Type: Literature]
View
28
[SID103209563]
IC50 0.04Concentration required to inhibit the HIV-1 reverse transcriptase activity by 50%. [AID197925, Type: Literature]Reverse transcriptase/RNaseH [gi:82310930]
View
29
[SID103209563]
IC50 0.04Inhibitory activity against HIV-1 recombinant reverse transcriptase. [AID198094, Type: Literature]Reverse transcriptase/RNaseH [gi:82310930]
View
30
[SID103209563]
IC50 0.04Inhibitory activity against HIV-1 mutant strain 100I [AID247495, Type: Literature]
View
31
[SID103209563]
IC50 0.04Inhibitory concentration required to inhibit the HIV-1 reverse transcriptase activity [AID199103, Type: Literature]
View
32
[SID103209563]
IC50 0.07Inhibitory activity against HIV-1 mutant strain 138K [AID247499, Type: Literature]
View
33
[SID103209563]
IC50 0.1Anti-HIV-1 activity against Y181C strain, in MT-4 cells by the MTT method [AID105704, Type: Literature]
View
34
[SID103209563]
IC50 0.12Inhibitory activity against HIV-1 mutant strain 101E [AID247496, Type: Literature]
View
35
[SID103209563]
IC50 0.15Inhibition of HIV1 reverse transcriptase by ELISA [AID481177, Type: Literature]
View
36
[SID103209563]
IC50 0.15Inhibition of HIV1 reverse transcriptase using poly(ra)/oligo(dT)15 homopolymer template as substrate after 1 hr [AID666410, Type: Literature]
View
37
[SID103209563]
IC50 0.27Ability to inhibit the replication of RT-MDR (V106A) strain of HIV-1 p24 antigen production in PBMC [AID155273, Type: Literature]
View
38
[SID103209563]
IC50 0.3Anti-HIV activity by its ability to inhibit the replication of HIV-1 strain RT-MDR(V106A) in peripheral blood mononuclear cells (PBMC) [AID155280, Type: Literature]
View
39
[SID103209563]
IC50 0.3Inhibitory activity of compound on p24 production in peripheral blood mononuclear cells infected with HIV strain RT-MDR. [AID152775, Type: Literature]
View
40
[SID103209563]
IC50 0.79Inhibitory activity against HIV-1 mutant strain 103N [AID247497, Type: Literature]
View
41
[SID103209563]
IC50 0.8Inhibition of recombinant reverse transcriptase (RT) in cell-free Quan-T-RT assay system [AID198229, Type: Literature]Reverse transcriptase/RNaseH [gi:82310930]
View
42
[SID103209563]
IC50 0.8Inhibition of purified recombinant HIV-1 reverse transcriptase [AID198231, Type: Literature]Reverse transcriptase/RNaseH [gi:82310930]
View
43
[SID103209563]
IC50 0.8Inhibitory activity against recombinant HIV-1 reverse transcriptase (rRT) [AID198228, Type: Literature]
View
44
[SID103209563]
EC50 1.26Compound was tested for its inhibition of HIV-1 induced focus formation in MAGI-CCR5 cells in strains like NL4-3K103N [AID102402, Type: Literature]
View
45
[SID103209563]
IC50 1.58Inhibitory activity against HIV-1 mutant strain 190A [AID247503, Type: Literature]
View
46
[SID103209563]
IC50 1.99Inhibitory activity against HIV-1 mutant strain 106A [AID247498, Type: Literature]
View
47
[SID103209563]
IC50 1.99Inhibitory activity against HIV-1 mutant strain 181C [AID247501, Type: Literature]
View
48
[SID103209563]
IC50 7.94Inhibitory activity against HIV-1 double mutants strain 101E and 103N [AID247618, Type: Literature]
View
49
[SID103209563]
IC50 7.94Inhibitory activity against HIV-1 mutant strain 190S [AID247504, Type: Literature]
View
50
[SID103209563]
EC50 13.4Compound was tested for its inhibition of HIV-1 induced focus formation in MAGI-CCR5 cells in strains like IIIB-R(Y181C) [AID102400, Type: Literature]
View